Sign In
Buy STAA
$28.26
-0.230 (-0.81%)
At Close: Jun 03, 2026
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
STAAR Surgical to Report First Quarter Results on May 7, 2024
07:00am, Monday, 29'th Apr 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
Star Surgical Shines as U.S. Outlook Improves for 2024
06:25am, Tuesday, 16'th Apr 2024
STAAR Surgical Co. NASDAQ: STAA develops and manufactures intraocular lenses (IOL) used to replace a person's natural lenses during cataract surgery. Its portfolio includes the EVO line of Implantable
Strength Seen in Staar Surgical (STAA): Can Its 16.5% Jump Turn into More Strength?
10:16am, Friday, 05'th Apr 2024
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
What's going on with STAAR Surgical shares?
10:13am, Friday, 05'th Apr 2024
STAAR Surgical (NASDAQ: STAA) received an upgrade from William Blair on Friday. The stock has been moved from Market Perform to Outperform status.
STAAR Surgical Announces Preliminary Net Sales for First Quarter 2024
07:00am, Thursday, 04'th Apr 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
STAAR Surgical Celebrates Three Million Lens Milestone at ASCRS Meeting, Unveils New EVO ICL Data and Latest Innovation for 2024
07:00am, Tuesday, 02'nd Apr 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, ast
STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses
07:00am, Monday, 18'th Mar 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
STAAR Surgical Company: Potential Buy After Long-Term Valuation Downgrade
10:43am, Wednesday, 13'th Mar 2024
STAAR Surgical Company's share price has experienced significant volatility, dropping over 60% in less than 9 months between 2022 and 2023. The company's 2023 earnings showed a 13% increase in net sal
STAAR Surgical Adds Arthur Butcher and Wei Jiang to Board of Directors
07:00am, Tuesday, 12'th Mar 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (ICL) for myopia, astigma
STAAR Surgical to Participate in Two Upcoming Investor Conferences
07:00am, Wednesday, 06'th Mar 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
Staar Surgical (STAA) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
03:01pm, Tuesday, 27'th Feb 2024
The headline numbers for Staar Surgical (STAA) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Stree
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
07:40pm, Monday, 26'th Feb 2024
STAAR Surgical Company (STAA) Q4 2023 Earnings Call Transcript
Staar Surgical (STAA) Beats Q4 Earnings Estimates
06:31pm, Monday, 26'th Feb 2024
Staar Surgical (STAA) came out with quarterly earnings of $0.24 per share, beating the Zacks Consensus Estimate of $0.19 per share. This compares to earnings of $0.14 per share a year ago.
STAAR Surgical to Report Fourth Quarter Results on February 26, 2024
07:00am, Monday, 19'th Feb 2024
LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia,
